A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Trial Profile

A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2018

At a glance

  • Drugs ABBV 368 (Primary) ; Nivolumab (Primary)
  • Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Non-small cell lung cancer; Oropharyngeal cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AbbVie
  • Most Recent Events

    • 27 Jul 2018 Planned number of patients changed from 100 to 150.
    • 27 Jul 2018 Planned End Date changed from 26 Feb 2020 to 8 Jul 2020.
    • 28 Feb 2018 Planned End Date changed from 16 Oct 2019 to 26 Feb 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top